| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NBL1 |
| Uniprot No | P41271 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-180aa |
| 氨基酸序列 | MMLRVLVGAV LPAMLLAAPP PINKLALFPD KSAWCEAKNI TQIVGHSGCE AKSIQNRACL GQCFSYSVPN TFPQSTESLV HCDSCMPAQS MWEIVTLECP GHEEVPRVDK LVEKILHCSC QACGKEPSHE GLSVYVQGED GPGSQPGTHP HPHPHPHPGG QTPEPEDPPG APHTEEEGAE D |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NBL1重组蛋白的参考文献示例(内容为虚构，供格式参考)：
---
1. **文献名称**：*Recombinant NBL1 Protein Inhibits Tumor Growth by Modulating TGF-β Signaling in Neuroblastoma*
**作者**：Smith, J. et al.
**摘要**：本研究通过大肠杆菌表达系统成功制备了重组NBL1蛋白，并验证其通过拮抗TGF-β信号通路抑制神经母细胞瘤细胞的增殖和迁移，为靶向治疗提供了实验依据。
2. **文献名称**：*Structural Characterization of NBL1 Reveals Key Domains for Apoptosis Induction*
**作者**：Zhang, L. & Wang, H.
**摘要**：利用X射线晶体学解析了重组NBL1的三维结构，发现其N端结构域与BMP(骨形态发生蛋白)结合，揭示了NBL1通过竞争性抑制促生长因子触发细胞凋亡的分子机制。
3. **文献名称**：*NBL1 Recombinant Protein Attenuates Fibrosis in a Mouse Liver Injury Model*
**作者**：Kim, S. et al.
**摘要**：在小鼠肝纤维化模型中，腹腔注射重组NBL1蛋白显著降低胶原沉积，证实其通过调控TGF-β/Smad通路抑制成纤维细胞活化，具有抗纤维化应用潜力。
4. **文献名称**：*High-Yield Production of Functional NBL1 in Mammalian Cells and Its Role in Angiogenesis*
**作者**：Garcia, R. et al.
**摘要**：通过哺乳动物细胞表达系统获得高活性重组NBL1.实验表明其通过抑制血管内皮生长因子(VEGF)信号通路，阻断肿瘤血管生成，为抗肿瘤药物开发提供新策略。
---
注：以上文献为示例性内容，实际研究中请通过PubMed、Google Scholar等平台检索真实发表的文章。
**Background of NBL1 Recombinant Protein**
NBL1 (Neuroblastoma suppressor of tumorigenicity 1), also known as DAN (Differential screening-selected gene Aberrative in Neuroblastoma), is a secreted protein encoded by the *NBL1/DAN* gene. It belongs to the DAN family of cysteine knot-secreted proteins, which are characterized by their ability to regulate cell growth and differentiation by modulating signaling pathways, particularly the TGF-β (transforming growth factor-beta) superfamily. NBL1 was initially identified as a tumor suppressor in neuroblastoma due to its downregulation in malignant tissues, implicating its role in inhibiting uncontrolled cell proliferation and tumorigenesis.
Functionally, NBL1 acts as a BMP (bone morphogenetic protein) antagonist, binding directly to BMP ligands to block their interaction with cell surface receptors. This antagonism modulates BMP-mediated processes such as osteogenesis, apoptosis, and embryonic development. Beyond oncology, NBL1 is involved in tissue homeostasis, wound healing, and organogenesis, highlighting its pleiotropic roles in both physiological and pathological contexts.
Recombinant NBL1 protein is produced using expression systems like *E. coli* or mammalian cells, ensuring proper folding and post-translational modifications for functional studies. It is widely utilized in research to investigate BMP signaling dynamics, cancer biology, and regenerative mechanisms. Its therapeutic potential is also being explored, particularly in diseases driven by BMP pathway dysregulation, such as fibrosis and certain cancers.
In summary, NBL1 recombinant protein serves as a critical tool for dissecting its biological functions and developing targeted therapies, bridging molecular insights with clinical applications.
×
